Mumbai: Cubo, an ultra-compact and affordable RT-PCR platform, is set to redefine access to molecular diagnostics as Avio Smart Market Stack Limited (ASMS) and Huwel Lifesciences announce its upcoming launch.
The platform has been developed to expand diagnostic accessibility across India and global healthcare systems, positioning Cubo as a significant innovation in decentralised healthcare delivery.
Avio Smart Market Stack Limited (ASMS), formerly known as Bartronics India Limited, in collaboration with Huwel Lifesciences, introduced Cubo as a first-of-its-kind indigenous platform that integrates laboratory-grade RT-PCR capabilities with a portable and cost-efficient deployment model.
With this launch, Cubo is expected to offer both organisations a strong early-mover advantage in one of the fastest-growing segments within healthcare technology.
Designed as a breakthrough in decentralised diagnostics, Cubo enables advanced molecular testing in a compact form factor, allowing deployment beyond traditional laboratory environments.
The platform can potentially bring high-end diagnostic capabilities to rural clinics, district hospitals, mobile health units, industrial sites, border regions, and remote geographies where access to centralised laboratories remains limited.
Also Read: Huwel Lifesciences and ASMS Onboard Singapore-Based Partner to Accelerate Southeast Asia Expansion
By enabling such accessibility, Cubo aligns with the broader push toward equitable healthcare delivery.
In many healthcare systems, diagnostic samples often require transportation over long distances to centralised labs, leading to delays and inefficiencies.
Cubo addresses this challenge by enabling accurate RT-PCR testing at or near the point of care, significantly reducing turnaround time and operational complexity.
This capability strengthens Cubo’s position within the global shift toward localised diagnostic ecosystems, offering a strategic advantage to early adopters.
The platform features a simplified workflow and an intuitive user interface, making it accessible for physicians and healthcare professionals across varied clinical environments.
Its ease of use, combined with portability, is expected to accelerate adoption compared to conventional systems that rely on extensive infrastructure and specialised settings.
Beyond its compact design, Cubo is being developed as a versatile diagnostic platform capable of supporting a wide range of assays.
These include tuberculosis, respiratory infections, influenza, viral panels, women’s health diagnostics, sexually transmitted infections, fever panels, and potential outbreak-response applications.
This broad testing capability positions Cubo to build a strong installed base over time and emerge as a leading solution in decentralised molecular diagnostics.
Also Read: Loopworm’s Silkworm-Based Nutrition Removes More CO₂ Than It Emits: PwC
Commenting on the product, Vidhya Sagar Reddy, Managing Director of ASMS, said, “Healthcare access should not be determined by geography. Cubo represents a major step toward bringing advanced diagnostics directly into underserved markets at scale.”
Shesheer Kumar, Managing Director of Huwel Lifesciences, added, “Cubo has been engineered to combine scientific precision with operational simplicity. Early leadership in compact molecular diagnostics can translate into sustained long-term market strength.”
The upcoming launch reflects a forward-looking vision from ASMS and Huwel Lifesciences, aiming to make advanced diagnostics accessible anywhere, usable by physicians across diverse settings, and scalable across India and global markets.
With its combination of portability, affordability, and diagnostic capability, the platform is positioned to play a key role in shaping the future of decentralised healthcare.
